Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 2, 2013, Pages 101-103

  Do Pazo Oubina F ^a   Estefanell Tejero, A ^a   Riu Viladoms, G ^a   Anglada Martinez H ^a   Molas Ferrer, G ^a   Creus Baro N ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

cetuximab; hypomagnesemia; magnesium; panitumumab

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; MAGNESIUM; PANITUMUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; ANTAGONISTS AND INHIBITORS; BLOOD; IMMUNOLOGY; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84874966969     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12028     Document Type: Article

References (11)

1. United States, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (v4.03: June 14, 2010). Available at: http://www.evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-Quick-Reference-8. 5x11.pdf (accessed 18 November 2012).
2. Izzedine H, Bahleda R, Khayat D, Massard C, Magne N, Spano JP, Soria JC,. Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol, 2010; 73: 213-219.
3. Groenestege WM, Thebault S, van der Wijst J, et al,. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest, 2007; 117: 2260-2267.
4. Erbitux (cetuximab) Summary of Product Characteristics 2009. Merck KGaA, Darmstadt, Germany. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000558/WC500029119.pdf (accessed 18 November 2012).
5. Jean GW, Shah SR,. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastasic colorectal cancer. Pharmacotherapy, 2008; 28: 742-754.
6. Fakih M,. Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. Oncology, 22: 2008; 74-76.
7. Tejpar S, Piessevaux H, Claes K, Piront P, Hoenderop JG, Verslype C, Van Cutsem E,. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol, 2007; 8: 387-394.
8. Cao Y, Liao C, Tan A, Liu L, Gao F,. Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer. Chemotherapy, 2010; 56: 459-465.
9. Fakih MG, Wilding G, Lombardo J,. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer, 2006; 6: 152-156.
10. Vincenzi B, Santini D, Galluzzo S, et al,. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res, 14: 2008; 4219-4224.
11. Vincenzi B, Galluzzo S, Santini D, et al,. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann Oncol, 2011; 22: 1141-1146.